px330 Search Results


94
Addgene inc px330 plasmid
Px330 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 plasmid/product/Addgene inc
Average 94 stars, based on 1 article reviews
px330 plasmid - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

92
Addgene inc px330 en479
Px330 En479, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 en479/product/Addgene inc
Average 92 stars, based on 1 article reviews
px330 en479 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

96
Addgene inc px330 u6 chimeric bbcbh hspcas9 plasmid
Px330 U6 Chimeric Bbcbh Hspcas9 Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 u6 chimeric bbcbh hspcas9 plasmid/product/Addgene inc
Average 96 stars, based on 1 article reviews
px330 u6 chimeric bbcbh hspcas9 plasmid - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier

94
Addgene inc nacl solution plasmid mix
Nacl Solution Plasmid Mix, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nacl solution plasmid mix/product/Addgene inc
Average 94 stars, based on 1 article reviews
nacl solution plasmid mix - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

93
Addgene inc plx330 lmna grna 1
Plx330 Lmna Grna 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plx330 lmna grna 1/product/Addgene inc
Average 93 stars, based on 1 article reviews
plx330 lmna grna 1 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc px330 flag wt spcas9
Px330 Flag Wt Spcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 flag wt spcas9/product/Addgene inc
Average 93 stars, based on 1 article reviews
px330 flag wt spcas9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

95
Addgene inc px330 plasmid expression cas9
Px330 Plasmid Expression Cas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 plasmid expression cas9/product/Addgene inc
Average 95 stars, based on 1 article reviews
px330 plasmid expression cas9 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

95
Addgene inc px330
Px330, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330/product/Addgene inc
Average 95 stars, based on 1 article reviews
px330 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

93
Addgene inc px330 flag wtspcas9 h840a

Px330 Flag Wtspcas9 H840a, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 flag wtspcas9 h840a/product/Addgene inc
Average 93 stars, based on 1 article reviews
px330 flag wtspcas9 h840a - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc spcas9

Spcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/spcas9/product/Addgene inc
Average 93 stars, based on 1 article reviews
spcas9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc p300 activity
(A-B) Percentage of HFK WT and <t>p300</t> KO cells with (A) colocalized RPA70 (green) and pDNA-PKcs (red) foci or (B) RAD51 (green) and pDNA-PKcs (red) foci over a 32-hour time course following zeocin exposure (10 μg/mL, 10 min). (C-D) Percentage of CCS1477 (1 μM) or DMSO treated HFK LXSN cells that contained colocalized (C) RPA70 (green) and pDNA-PKcs (red) or (D) RAD51 (green) and pDNA-PKcs (red) foci following zeocin treatment. (E-F) Percentage of primary HFK cells treated with CCS1477 or DMSO that contained (E) colocalized RPA70 and pDNA-PKcs foci 16-hours following zeocin treatment or (F) RAD51 and pDNA-PKcs foci 24-hours following zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (0 h) and zeocin treated group within each cell line. At least 150 cells were counted over three independent experiments.
P300 Activity, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p300 activity/product/Addgene inc
Average 93 stars, based on 1 article reviews
p300 activity - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Addgene inc px330 flag hypaspcas9
(A-B) Percentage of HFK WT and <t>p300</t> KO cells with (A) colocalized RPA70 (green) and pDNA-PKcs (red) foci or (B) RAD51 (green) and pDNA-PKcs (red) foci over a 32-hour time course following zeocin exposure (10 μg/mL, 10 min). (C-D) Percentage of CCS1477 (1 μM) or DMSO treated HFK LXSN cells that contained colocalized (C) RPA70 (green) and pDNA-PKcs (red) or (D) RAD51 (green) and pDNA-PKcs (red) foci following zeocin treatment. (E-F) Percentage of primary HFK cells treated with CCS1477 or DMSO that contained (E) colocalized RPA70 and pDNA-PKcs foci 16-hours following zeocin treatment or (F) RAD51 and pDNA-PKcs foci 24-hours following zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (0 h) and zeocin treated group within each cell line. At least 150 cells were counted over three independent experiments.
Px330 Flag Hypaspcas9, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/px330 flag hypaspcas9/product/Addgene inc
Average 93 stars, based on 1 article reviews
px330 flag hypaspcas9 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Journal: eLife

Article Title: PEAR, a flexible fluorescent reporter for the identification and enrichment of successfully prime edited cells

doi: 10.7554/eLife.69504

Figure Lengend Snippet:

Article Snippet: Plasmids acquired from the non-profit plasmid distribution service Addgene were the following: pCMV-PE2 (#132775) , pAT9624-BEAR-cloning (#162986), pAT9651-BEAR-GFP (#162989), pAT9752-BEAR-mScarlet (#162991), pAT9658-sgRNA-mCherry (#162987), pAT9679-sgRNA-BFP (#162988) , pX330-Flag-wtSpCas9-H840A (#80453), pX330-Flag-dSpCas9 (#92113), and pX330-Flag-wtSpCas9 (#92353) ( ).

Techniques: Recombinant, Sequencing

(A-B) Percentage of HFK WT and p300 KO cells with (A) colocalized RPA70 (green) and pDNA-PKcs (red) foci or (B) RAD51 (green) and pDNA-PKcs (red) foci over a 32-hour time course following zeocin exposure (10 μg/mL, 10 min). (C-D) Percentage of CCS1477 (1 μM) or DMSO treated HFK LXSN cells that contained colocalized (C) RPA70 (green) and pDNA-PKcs (red) or (D) RAD51 (green) and pDNA-PKcs (red) foci following zeocin treatment. (E-F) Percentage of primary HFK cells treated with CCS1477 or DMSO that contained (E) colocalized RPA70 and pDNA-PKcs foci 16-hours following zeocin treatment or (F) RAD51 and pDNA-PKcs foci 24-hours following zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (0 h) and zeocin treated group within each cell line. At least 150 cells were counted over three independent experiments.

Journal: PLoS Pathogens

Article Title: Beta human papillomavirus 8 E6 allows colocalization of non-homologous end joining and homologous recombination repair factors

doi: 10.1371/journal.ppat.1010275

Figure Lengend Snippet: (A-B) Percentage of HFK WT and p300 KO cells with (A) colocalized RPA70 (green) and pDNA-PKcs (red) foci or (B) RAD51 (green) and pDNA-PKcs (red) foci over a 32-hour time course following zeocin exposure (10 μg/mL, 10 min). (C-D) Percentage of CCS1477 (1 μM) or DMSO treated HFK LXSN cells that contained colocalized (C) RPA70 (green) and pDNA-PKcs (red) or (D) RAD51 (green) and pDNA-PKcs (red) foci following zeocin treatment. (E-F) Percentage of primary HFK cells treated with CCS1477 or DMSO that contained (E) colocalized RPA70 and pDNA-PKcs foci 16-hours following zeocin treatment or (F) RAD51 and pDNA-PKcs foci 24-hours following zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (0 h) and zeocin treated group within each cell line. At least 150 cells were counted over three independent experiments.

Article Snippet: CCS1477 (CT-CCS1477, Chemietek) was used to inhibit p300 activity (1 μM). sgRNA/CAS9 plasmids (#136938, Addgene) were used to generate a DSB for next-generation sequencing.

Techniques: Control

(A-B) Percentage of HFK WT and HFK p300 KO cells with RAD51 staining in G1 as determined by (A) Cyclin E staining or (B) flow cytometry after zeocin treatment (10 μg/mL, 10 min). (C-D) Percentage of HFK LXSN cells treated with DMSO or CCS1477 (1 μM) that had RAD51 staining in G1 as determined by (C) Cyclin E staining or (D) flow cytometry after zeocin treatment. (E-F) Percentage of primary HFK LXSN cells treated with DMSO or CCS1477 that had RAD51 staining in G1 as determined by (E) Cyclin E staining or (F) flow cytometry after zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (solvent) and treated group within each cell line. At least 150 cells were counted over three independent experiments for microscopy. Twenty thousand cells were counted for each of three independent flow cytometry experiments.

Journal: PLoS Pathogens

Article Title: Beta human papillomavirus 8 E6 allows colocalization of non-homologous end joining and homologous recombination repair factors

doi: 10.1371/journal.ppat.1010275

Figure Lengend Snippet: (A-B) Percentage of HFK WT and HFK p300 KO cells with RAD51 staining in G1 as determined by (A) Cyclin E staining or (B) flow cytometry after zeocin treatment (10 μg/mL, 10 min). (C-D) Percentage of HFK LXSN cells treated with DMSO or CCS1477 (1 μM) that had RAD51 staining in G1 as determined by (C) Cyclin E staining or (D) flow cytometry after zeocin treatment. (E-F) Percentage of primary HFK LXSN cells treated with DMSO or CCS1477 that had RAD51 staining in G1 as determined by (E) Cyclin E staining or (F) flow cytometry after zeocin treatment. All values are represented as mean ± standard error. The statistical significance of differences between cell lines or treatments were determined using Student’s t-test. * indicates significant difference between two groups (A-D) or LXSN and 8E6 (E-F) with same treatment (p< 0.05). # indicates p < 0.05 between control (solvent) and treated group within each cell line. At least 150 cells were counted over three independent experiments for microscopy. Twenty thousand cells were counted for each of three independent flow cytometry experiments.

Article Snippet: CCS1477 (CT-CCS1477, Chemietek) was used to inhibit p300 activity (1 μM). sgRNA/CAS9 plasmids (#136938, Addgene) were used to generate a DSB for next-generation sequencing.

Techniques: Staining, Flow Cytometry, Control, Solvent, Microscopy

(i) DSB occurs in a cell in G1 phase that is expressing 8E6. (ii) NHEJ initiates. DNA-PKcs is recruited to the lesion where it is auto-phosphorylated. (iii) NHEJ stalls due to 8E6 mediated p300 degradation. This leaves unresolved pDNA-PKcs repair complexes . (iv) HR initiates at the site of failed NHEJ. The MRN complex, CtIP, and EXO1 resect one strand of DNA near the lesion, producing single stranded DNA . RPA complexes coat and stabilize the resulting single stranded DNA . RPA70 foci colocalize with pDNA-PKcs indicating that HR-mediated DNA resection occurs after NHEJ fails. Then, RAD51 is recruited to the break site. (v) HR cannot be complete due to the lack of a homologous template and/or 8E6-mediated inhibition of HR . This causes deletions due to antagonist DNA end process by NHEJ and HR and/or by failure to complete HR after resection. (vi) The failure of NHEJ causes cells to use tertiary DSB repair pathways to fix the lesion. (vii) This alternative repair pathway (e.g., Alt-EJ) is error prone and increases other types of mutations (such as SNPs).

Journal: PLoS Pathogens

Article Title: Beta human papillomavirus 8 E6 allows colocalization of non-homologous end joining and homologous recombination repair factors

doi: 10.1371/journal.ppat.1010275

Figure Lengend Snippet: (i) DSB occurs in a cell in G1 phase that is expressing 8E6. (ii) NHEJ initiates. DNA-PKcs is recruited to the lesion where it is auto-phosphorylated. (iii) NHEJ stalls due to 8E6 mediated p300 degradation. This leaves unresolved pDNA-PKcs repair complexes . (iv) HR initiates at the site of failed NHEJ. The MRN complex, CtIP, and EXO1 resect one strand of DNA near the lesion, producing single stranded DNA . RPA complexes coat and stabilize the resulting single stranded DNA . RPA70 foci colocalize with pDNA-PKcs indicating that HR-mediated DNA resection occurs after NHEJ fails. Then, RAD51 is recruited to the break site. (v) HR cannot be complete due to the lack of a homologous template and/or 8E6-mediated inhibition of HR . This causes deletions due to antagonist DNA end process by NHEJ and HR and/or by failure to complete HR after resection. (vi) The failure of NHEJ causes cells to use tertiary DSB repair pathways to fix the lesion. (vii) This alternative repair pathway (e.g., Alt-EJ) is error prone and increases other types of mutations (such as SNPs).

Article Snippet: CCS1477 (CT-CCS1477, Chemietek) was used to inhibit p300 activity (1 μM). sgRNA/CAS9 plasmids (#136938, Addgene) were used to generate a DSB for next-generation sequencing.

Techniques: Expressing, Inhibition